Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Bellicum Pharmaceuticals, Inc. closed up 13.86% yesterday and headed higher another 5.43% in after-hours trading. The stock also had unusually high volume yet no remarkable news to explain it or the gains. Some hedge funds have recently been increasing or decreasing their stakes in the company. According to a recent disclosure with the SEC, Kennedy Capital Management has upped its stake in the pharmaceutical company by 32.1% in the first quarter. Bank of New York Mellon Corp grew its stake in the company by 1.0% in the first quarter and Capital Fund Management S.A. purchased a new stake in Bellicum Pharmaceuticals during the period that was valued at approximately $539,000. Eagle Ridge Investment Management also purchased a new stake in the company during Q1 that was valued at approximately $144,000.
